Vitrolife AB (publ) becomes lead investor in AutoIVF

Rhea-AI Summary

Vitrolife Group (VTRLY) has announced a strategic investment in AutoIVF, becoming its lead investor. AutoIVF is developing OvaReady™, an automated system that streamlines egg retrieval and preparation in IVF procedures. The technology aims to enhance fertility services and enable egg retrieval outside traditional IVF lab settings.

This investment aligns with Vitrolife's strategy to develop an end-to-end platform connecting products and services across the IVF workflow. The financial impact is described as minimal, with more details to be disclosed during Q2 earnings. The partnership aims to accelerate AutoIVF's path to market and expand access to fertility care through automation and innovation.

Positive

• Strategic investment aligns with corporate strategy to improve IVF accessibility and affordability
• Investment strengthens Vitrolife's position in automated IVF solutions
• Partnership could enable expansion of IVF services beyond traditional laboratory settings

Negative

• Financial impact described as minimal, suggesting limited near-term revenue contribution
• Early-stage investment carries inherent technology and market adoption risks

GOTHENBURG, Sweden, May 8, 2025 /PRNewswire/ -- The Vitrolife Group today announces it has become a leading investor in AutoIVF. This strategic investment aligns with our corporate strategy of improving affordability and access to IVF to patients around the world.

AutoIVF, is an early-stage MedTech company with the aim to make IVF more accessible, affordable and efficient. Its technology, OvaReady™, is a groundbreaking automated system that simplifies and enhances egg retrieval and preparation, enabling high-quality fertility services in the current IVF process and also supports decentralising the egg retrieval process outside traditional IVF laboratory settings. 

''This investment marks another step in our corporate strategy to build an end-to-end platform that connects products and services across the entire IVF workflow. By continuing to automate the IVF process we will enable safe, efficient and effective fertility care," says Bronwyn Brophy O'Connor, CEO of the Vitrolife Group.

Ravi Kapur, CEO of AutoIVF, shares, "With this new investment and partnership, we are excited to accelerate our path to market and explore collaborations that can expand access, scale innovation, and create lasting value across the reproductive health ecosystem."

Financial impact is minimal, more details will be disclosed during the Q2 earnings release.

Gothenburg, May 8, 2025 
VITROLIFE AB (publ)
Bronwyn Brophy O'Connor, CEO

Contact:
Amelie Wilson, Investor Relations, awilson@vitrolife.com 

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/vitrolife-ab--publ-/r/vitrolife-ab--publ--becomes-lead-investor-in-autoivf,c4147438

The following files are available for download:

https://mb.cision.com/Main/1031/4147438/3438153.pdf

Vitrolife AB (publ) becomes lead investor in AutoIVF

View original content:https://www.prnewswire.com/news-releases/vitrolife-ab-publ-becomes-lead-investor-in-autoivf-302450133.html

SOURCE Vitrolife AB

FAQ

What is the purpose of Vitrolife's (VTRLY) investment in AutoIVF?

Vitrolife's investment in AutoIVF aims to improve IVF accessibility and affordability while developing an end-to-end platform for IVF workflow. The investment supports their strategy of automating IVF processes to enable safe, efficient fertility care.

What is AutoIVF's OvaReady™ technology?

OvaReady™ is an automated system that simplifies egg retrieval and preparation in IVF procedures. It's designed to enhance fertility services and enable egg retrieval outside traditional IVF laboratory settings.

What is the financial impact of Vitrolife's investment in AutoIVF?

The financial impact is described as minimal, with more detailed information to be disclosed during Vitrolife's Q2 earnings release.

How will this investment benefit Vitrolife's (VTRLY) business strategy?

The investment supports Vitrolife's strategy to build an end-to-end platform connecting IVF products and services, while advancing automation in fertility care to make it more accessible and efficient.